Medical Practice Technical Challenges


Non-Hodgkin Lymphomas: From Biology to Treatment

Applications to the current course are now closed.
<< back to courses index
May 18th 2022 - May 19th 2022
Maria Gomes da Silva (MD, PhD) , 
José Cabeçadas (MD)
Lymphomas are frequent haematological tumours comprising approximately 4% of all cancers.
They are characterized by a highly heterogeneous clinical presentation that mirrors a rich diversity of
biological features and pathogenic mechanisms. The diagnosis is based on the integration of
morphological, phenotypical, genetic and clinical data. Recent technological advances in the flow
cytometry and mostly the genomic fields have greatly contributed to the granular classification and
current understanding of these tumours.
This detailed classification, frequently including molecular characteristics, in turn form the basis for
modern therapeutic options. Aggressive lymphomas, including mostly diffuse large cell lymphoma,
are the most frequent subtype and may be cured in a significant fraction of patients. Patients failing
first line treatment used to have a poor prognosis, that is being changed by a significant number of
recently approved new drugs and treatment modalities. Indolent B cell lymphomas evolve for very
prolonged periods of time; they remain mostly incurable although many new therapies, including
targeted agents, are becoming available.
Hodgkin lymphomas are curable in the vast majority of cases and relapsed and refractory patients
have nowadays effective therapeutic options such as antibody drug conjugates and checkpoint
inhibitors. The research agenda in the lymphoma field currently includes, among other subjects, the
detailed biological characterization, innovative therapies and toxicity prevention.
MDs working in the areas of haematology and pathology, including trainees.
  1. To understand the normal immune response and its relationship to lymphomagenesis
  2. To understand the basis of lymphoma diagnosis and treatment based on the above
  3. To review the diagnostic methods and their complementarity
  4. To understand the current classification of lymphomas and main features of common entities
  5. To discuss integrated treatment approaches, including chemotherapy, immunotherapy and cellular therapies applicable to the field of lymphomas
  6. To apply the described concept to clinical cases
  7. To understand the key areas for research in the field
Attendees should be engaged in active practice in the field of diagnosis and/or lymphoma patient care.